Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058159 | 0.87 | IDO1 (0.41) | IDO1ADRB2NCF1GAKCYP3A4 | |
| SCHEMBL12213692 | 0.86 | IDO1 (0.41) | IDO1ADRB2NCF1GAKCYP3A4 | |
| SCHEMBL12237059 | 0.83 | HCRTR2 (0.42) | IDO1CYP3A4 | |
| SCHEMBL14877482 | 0.78 | ADRB2 (0.44) | IDO1ADRB2NCF1GAKCYP3A4 | |
| SCHEMBL8277163 | 0.74 | IDO1 (0.40) | IDO1ADRB2NCF1GAKCYP3A4 | |
| SCHEMBL10025294 | 0.72 | HTR1A (0.34) | IDO1CYP3A4AAK1 | |
| SCHEMBL12237060 | 0.71 | ALDH1A1 (0.44) | IDO1CYP3A4THRB | |
| SCHEMBL10025309 | 0.71 | LMNA (0.41) | IDO1CYP3A4 | |
| SCHEMBL12213693 | 0.70 | HTR1A (0.39) | GAKCYP3A4 | |
| SCHEMBL10058161 | 0.70 | HTR1A (0.41) | GAKCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| US-7365092-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | IDO1 1224/4885ADRB2 4810/4885NCF1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.